Radius Health has been granted a patent for methods of analyzing abaloparatide samples for isomers and storing/treating abaloparatide in light of newly discovered isomers. The patent includes a claim for an isomer of abaloparatide with a specific sequence. GlobalData’s report on Radius Health gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Radius Health Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Radius Health, Microneedles for transdermal drug delivery was a key innovation area identified from patents. Radius Health's grant share as of May 2024 was 31%. Grant share is based on the ratio of number of grants to total number of patents.

Analyzing and treating abaloparatide samples for isomers

Source: United States Patent and Trademark Office (USPTO). Credit: Radius Health Inc

A recently granted patent (Publication Number: US11977067B2) discloses an isomer of abaloparatide that includes beta-Asp10 abaloparatide in its sequence. This isomer, as described in claim 2, consists solely of beta-Asp10 abaloparatide. The patent further extends to claim 3, which encompasses a pharmaceutical composition containing this specific abaloparatide isomer.

Moreover, the pharmaceutical composition detailed in the patent not only includes the abaloparatide isomer but also incorporates abaloparatide itself, as stated in claim 4. Additionally, the composition is formulated with an aqueous buffer, as per claim 5, and maintains a pH range between about 4 to 6, as specified in claims 6 and 7. It is worth noting that the pharmaceutical composition described in the patent is intended to be a formulated drug product, as outlined in claim 8.

To know more about GlobalData’s detailed insights on Radius Health, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies